The prevalence of obesity and overweight is increasing in mood disorder, and it is connected to an increased cardiovascular mortality. Because of them, treatment for obesity may be an essential part of mood disorder treatment. Similar to the general population, non-pharmacological treatment such as correction of life habits should be considered first of all. If this approaches are fail, pharmacological treatment for obesity would be required as next step. Any drug for obesity is not approved officially in mood disorder. So approved drugs in general population, and drugs supported by several studies are prescribed in clinical settings. Several treatment guidelines for mood disorder and studies support that orlistat, metformin, topiramate and bupropion is effective and safe.
Bupropion ; Drug Therapy* ; Metformin ; Mood Disorders* ; Mortality ; Obesity* ; Overweight ; Prevalence

Objectives: ：Although dysfunctional breathing is a common symptom in general population and affects qual-ities of life, it is still underdiagnosed. There are some studies of prevalence of it in astma, but few studies in anxiety and depressive disorders. The purposes of this study were to explore the prevalence of it in anxiety and depressive disorders, and to investigate whether anxiety and depressed mood influence it. Methods: ：135 patients diagnosed with anxiety or depressive disorders, and 124 controls were recruited. Ni-jmegen questionnaire was used to assess dysfunctional breathing, and Hospital anxiety depression scale was used. Results: ：The prevalence of dysfunctional breathing in anxiety or depressive disorders was higher than that in control. In the linear regression model, anxiety accounted for 59.6% of dysfunctional breathing, but depressed mood did not. With covariate adjusted for anxiety, scores of dysfunctional breathing in anxiety or depressive disorders were higher than in controls. Conclusions ：Dysfunctional breathing in anxiety or depressive disorders is higher than that in control. Adjust-ing anxiety, its difference is still. Anxiety affects dysfunctional breathing, but depressed mood does not.

BACKGROUND AND OBJECTIVES: Although Ling 6 sounds are often used in the rehabilitation process, its acoustic features have not been fully analyzed and represented in cortical responses. Current study was aimed to analyze acoustic features according to gender and emotional statuses of core vowels of Ling 6 sounds, /u/, /a/, and /i/. Cortical auditory evoked potentials (CAEPs) were also observed in those vowels. SUBJECTS AND METHODS: Vowel sounds /u/, /a/, and /i/ out of Ling 6 sounds representing low, middle and high frequencies were recorded from normal 20 young adults. The participants watched relevant videos for 4-5 minutes in order for them to sympathize emotions with anger (A), happiness (H), and sadness (S) before producing vowels. And without any emotional salience, neutrally production was performed. The recording was extracted for 500 ms to select pure vowel portion of production. For analysis of CAEP, the latencies and amplitudes of P1, N1, P2, N2, N1-P2 were analyzed. RESULTS: Intensities of /u/, /a/, and /i/ were 61.47, 63.38, and 60.55 dB. The intensities of neutral (N), H, A, S were 60.60, 65.43, 64.21, and 55.75 dB for vowel /u/, vowel /a/ were 61.80, 68.98, 66.50, and 56.23 dB, and vowel /i/ were 59.34, 64.90, 61.90, and 56.05 dB. The statistical significances for vowel and emotion were found but not for gender. The fundamental frequency (F0) of vowels for N, A, H, and S were 168.04, 174.93, 182.72, and 149.76 Hz and the first formant were 743.75, 815.59, 823.32, and 667.62 Hz. The statistical significance of F0 was found by vowel, emotion, and gender. The latencies and amplitudes of CAEP components did not show any statistical significance according to vowel. CONCLUSIONS: Ling 6 sounds should be produced consistently in the rehabilitation process for considering their difference of intensities and frequencies according to speaker’s emotions and gender. The vowels seemed to be interpreted as tonal stimuli for CAEP components of this study with similar acoustic features among them. Careful selection of materials is necessary to observe meaningful conclusion of CAEP measurement with vowel stimuli.
Acoustics ; Anger ; Evoked Potentials, Auditory ; Happiness ; Humans ; Rehabilitation ; Young Adult

As the government has a plan to terminate medical internships and to start the New Resident program, postgraduate medical students should encounter the new residency training program without the internship from 2015. To keep pace with this significant change, the Korean Neuropsychiatry association launched the task force team to manage this problem. The task force team has examined the psychiatry residency training programs from major countries, including England, Japan, Germany, Australia, New Zealand, and the Unites States. In addition, we conducted a survey for teaching psychiatrists and psychiatry residents who just finished the Psychiatry Board Examination in 2013 using a premade questionnaire on the expected problems that might occur if the internship program were abolished, and some significant issues regarding resident rotation schedule to other departments. In this paper, we summarized the results of our examination and survey. Establishment of a new residency training program based on these surveys would be desirable.
Advisory Committees ; Appointments and Schedules ; Australia ; England ; Germany ; Humans ; Internship and Residency ; Japan ; Korea ; Neuropsychiatry ; New Zealand ; Psychiatry ; Surveys and Questionnaires ; Students, Medical

This guideline outlines the use of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on inter-national standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effec-tive application of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma. It also addresses the use of premedication with carbidopa, fasting protocols, and optimal imaging techniques. The aim is to assist nuclear medicine professionals in delivering precise diagnoses, improving patient outcomes, and accommodating evolving medical knowl-edge and technology. This comprehensive document serves as a practical resource to enhance the accuracy, quality, and safety of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography in oncology.

This guideline outlines the use of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on inter-national standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effec-tive application of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma. It also addresses the use of premedication with carbidopa, fasting protocols, and optimal imaging techniques. The aim is to assist nuclear medicine professionals in delivering precise diagnoses, improving patient outcomes, and accommodating evolving medical knowl-edge and technology. This comprehensive document serves as a practical resource to enhance the accuracy, quality, and safety of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography in oncology.

This guideline outlines the use of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on inter-national standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effec-tive application of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma. It also addresses the use of premedication with carbidopa, fasting protocols, and optimal imaging techniques. The aim is to assist nuclear medicine professionals in delivering precise diagnoses, improving patient outcomes, and accommodating evolving medical knowl-edge and technology. This comprehensive document serves as a practical resource to enhance the accuracy, quality, and safety of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography in oncology.

This guideline outlines the use of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on inter-national standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effec-tive application of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma. It also addresses the use of premedication with carbidopa, fasting protocols, and optimal imaging techniques. The aim is to assist nuclear medicine professionals in delivering precise diagnoses, improving patient outcomes, and accommodating evolving medical knowl-edge and technology. This comprehensive document serves as a practical resource to enhance the accuracy, quality, and safety of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography in oncology.

This guideline outlines the use of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on inter-national standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effec-tive application of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma. It also addresses the use of premedication with carbidopa, fasting protocols, and optimal imaging techniques. The aim is to assist nuclear medicine professionals in delivering precise diagnoses, improving patient outcomes, and accommodating evolving medical knowl-edge and technology. This comprehensive document serves as a practical resource to enhance the accuracy, quality, and safety of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography in oncology.

OBJECTIVE: To compare real-life clinical outcomes with the levonorgestrel-releasing intrauterine system (LNG-IUS) and conventional medical therapies (CMTs), including combined oral contraceptives and oral progestins in the treatment of idiopathic heavy menstrual bleeding (HMB) in South Korea. METHODS: This prospective, observational cohort study recruited a total of 647 women aged 18 to 45 years, diagnosed with HMB from 8 countries in Asia, including 209 women from South Korea (LNG-IUS, 169; CMTs, 40), who were followed up to one year. The primary outcome was cumulative continuation rate (still treated with LNG-IUS and CMTs) at 12 months. Secondary outcomes included bleeding pattern, assessment of the treatment efficacy by treating physician and safety profile. RESULTS: The continuation rate at 12 months was significantly higher with the LNG-IUS than CMTs (85.1% vs. 48.5%, respectively; P<0.0001). The 51.5% of CMTs patients discontinued treatment and 18.8% of LNG-IUS patients discontinued treatment. The most common reasons for discontinuation for CMTs were switching to another treatment and personal reasons. When compared to CMTs, the LNG-IUS offered better reduction in subjectively assessed menstrual blood loss and the number of bleeding days, tolerability and with better efficacy in HMB, as assessed by physician's final evaluation. CONCLUSION: This study provides novel information on the real-life treatment patterns of HMB in South Korea. The efficacy of CMTs was inferior compared to the LNG-IUS in the clinical outcomes measured in this study. Due to the better compliance with LNG-IUS, the cumulative continuation rate is higher than CMTs. We conclude that the LNG-IUS should be used as the first-line treatment for HMB in Korean women, in line with international guidelines.
Asia ; Asian Continental Ancestry Group* ; Cohort Studies ; Compliance ; Contraceptives, Oral, Combined ; Female ; Hemorrhage* ; Humans ; Korea ; Progestins ; Prospective Studies ; Treatment Outcome